WO2007096088A1 - Préparations efficaces contre les impuretés cutanées et les formes bénignes de l'acné, contenant de l'hydroxymatairésinol comme principe actif - Google Patents

Préparations efficaces contre les impuretés cutanées et les formes bénignes de l'acné, contenant de l'hydroxymatairésinol comme principe actif Download PDF

Info

Publication number
WO2007096088A1
WO2007096088A1 PCT/EP2007/001352 EP2007001352W WO2007096088A1 WO 2007096088 A1 WO2007096088 A1 WO 2007096088A1 EP 2007001352 W EP2007001352 W EP 2007001352W WO 2007096088 A1 WO2007096088 A1 WO 2007096088A1
Authority
WO
WIPO (PCT)
Prior art keywords
acne
hydroxymatairesinol
oil
preparations
mild forms
Prior art date
Application number
PCT/EP2007/001352
Other languages
German (de)
English (en)
Inventor
Anette Bürger
Svena Cerv
Julia Eckert
Ludger Kolbe
Christopher Mummert
Gitta Neufang
Michael WÖHRMANN
Original Assignee
Beiersdorf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf Ag filed Critical Beiersdorf Ag
Publication of WO2007096088A1 publication Critical patent/WO2007096088A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations

Definitions

  • the present invention relates to active ingredients and preparations containing such active ingredients which are effective against blemished skin and mild forms of acne.
  • Impure skin and / or comedones affect the well-being of those affected but even in mild cases. Since virtually every adolescent or person is affected by blemished skin of some kind, many people need to remedy this condition.
  • Object of the present invention was therefore to find against blemished skin, mild forms of acne or Propionibacterium acnes active substance.
  • Hydroxymatairesinol is a so-called lignan.
  • Lignans are dimers of phenylpropane derivatives which are linked to one another via the C-2 atom of the propane chain (2,2'-linkage). These are mostly colorless, crystalline, hardly volatile compounds without odor and striking taste. They are formed as compounds of plant secondary metabolism probably by radical-oxidative coupling of two phenylpropane derivatives.
  • Hydroxymatairesinol as such occurs in the spruce (Picea abies) and is obtainable, for example, by methods as described by Eklund, Lindholm, Mikkola, Smeda, Lehtilä and Söholm in the essay "Synthesis of (-) - matairesinol, (-) - enterolactone, and (-) - enterodiol from the natural lignan hydroxymatairesinol "in Org. Lett.2003, 5, pp. 491-493.
  • the cosmetic preparations according to the invention against blemished skin or against mild forms of acne are particularly advantageously characterized in that the hydroxymatairesinol is present in concentrations of 0.05-10.00% by weight, preferably 0.1-5.0% by weight. , in each case based on the total weight of the preparations.
  • the preparations according to the invention which are active against blemished skin or mild forms of acne may be in the form of liquid compositions which can be applied by means of paint brushes or wipers or roll-on devices, as pens and in the form of W / O or O can be applied from normal bottles and containers.
  • W emulsions eg Creams or lotions.
  • the preparations according to the invention which are active against impure skin can advantageously be in the form of face lotions, tinctures or cleansing formulations.
  • emulsifiers for the preparation of the present invention against blemished skin or mild forms of acne effective preparations which are advantageously applied as liquid preparations to the desired areas of the skin, preferably by means of a cotton swab, and in the preparations in a small amount, e.g. 2 to 5 weight. % based on the total composition
  • nonionic types such as polyoxyethylene fatty alcohol ethers, e.g.
  • pH preferably e.g. is adjusted to 4.0 to 9.0, in particular 5.0 to 6.5
  • perfume dyes
  • BHT 2,6-di-tert.
  • the pH of the preparations according to the invention which are active against blemished skin or against mild forms of acne is advantageously adjusted in the weakly acidic to neutral range, preferably from 4.0 to 7.0, particularly preferably from 5.0 to 6.5.
  • the cosmetic and / or dermatological formulations according to the invention may be composed as usual and used for the treatment of the skin and / or the hair in the sense of a dermatological treatment or a treatment in the sense of nourishing cosmetics. NEN. But they can also be used in make-up products in decorative cosmetics or in the cosmetic and dermatological cleaning products.
  • Cosmetic and dermatological preparations according to the invention also e.g. to protect the skin from UV rays may be in various forms, such as e.g. Usually used for this type of preparations. So they can e.g. a solution, a water-in-oil (W / O) or oil-in-water (O / W) type emulsion, or a multiple emulsions, such as water-in-oil-in-water (W / O / W), oil-in-water-in-oil (O / W / O), a gel, a hydrodispersion, a lamellar phase, a liquid isotropic solution phase, a micellar phase, a solid or dispersed one or more times hexagonal phase, a solid or dispersed single or multi-cubic phase, a lyotropic phase, a crystalline phase, a solid stick or even an aerosol.
  • W / O water-in-oil
  • O / W oil-in-water
  • the active compounds according to the invention can also be used with particular advantage in microemulsions, for example as described in German Offenlegungsschrift DE-195 9 079.
  • the oil phase of the preparations according to the invention is advantageously selected from the group of esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols having a chain length of 3 to 30 carbon atoms.
  • ester oils can then advantageously be selected from the group consisting of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2 Hexyldecyl stearate, 2-octyldodecyl palmitate, oleyl oleate, oleyl erucate, erucyl oleate, erucyl erucate, as well as synthetic, semi-synthetic and natural mixtures of such esters, eg Jojoba oil.
  • the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and the fatty acid triglycerides, namely the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 8 to 24, in particular 12 - 18 C atoms.
  • the fatty acid triglycerides can be selected, for example, advantageously from the group of synthetic, semi-synthetic and natural oils, such as olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like.
  • the oil phase selected from the group 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C 12 -i 5 alkyl benzoate, caprylic-capric acid triglyceride, dicaprylyl ether.
  • Particularly advantageous are mixtures of C 12-15 -alkyl benzoate and 2-ethylhexyl isostearate, mixtures of C 12-15 -alkyl benzoate and isotridecyl isononanoate and mixtures of C 12 - I5 - benzoate, 2-ethylhexyl isostearate and isotridecyl isononanoate.
  • hydrocarbons paraffin oil, squalane and squalene are to be used advantageously in the context of the present invention.
  • the oil phase may further comprise a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or silicone oils.
  • cyclomethicone octamethylcyclotetrasiloxane
  • silicone oils are also advantageous for the purposes of the present invention, for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane).
  • mixtures of cyclomethicone and isotridecyl isononanoate, cyclomethicone and 2-ethylhexyl isostearate are particularly advantageous.
  • the content of the oil phase is between 1 and 50 wt .-%, based on the total weight of the preparations, preferably 2.5 to 30 wt .-%, particularly preferably 5 to 15 wt .-%.
  • the cosmetic and / or dermatological formulations according to the invention are applied to the skin and / or the hair in a sufficient amount in the manner customary for cosmetics and dermatological agents.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)

Abstract

Utilisation d'hydroxymatairésinol comme principe actif contre les impuretés de la peau, les formes bénignes de l'acné et/ou contre Propionibacterium acnes.
PCT/EP2007/001352 2006-02-22 2007-02-16 Préparations efficaces contre les impuretés cutanées et les formes bénignes de l'acné, contenant de l'hydroxymatairésinol comme principe actif WO2007096088A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006008771.2 2006-02-22
DE102006008771A DE102006008771A1 (de) 2006-02-22 2006-02-22 Gegen unreine Haut und milde Formen der Akne wirksame Zubereitungen mit einem Gehalt an Hydroxymatairesinol als wirksames Prinzip

Publications (1)

Publication Number Publication Date
WO2007096088A1 true WO2007096088A1 (fr) 2007-08-30

Family

ID=38042536

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/001352 WO2007096088A1 (fr) 2006-02-22 2007-02-16 Préparations efficaces contre les impuretés cutanées et les formes bénignes de l'acné, contenant de l'hydroxymatairésinol comme principe actif

Country Status (2)

Country Link
DE (1) DE102006008771A1 (fr)
WO (1) WO2007096088A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009101262A3 (fr) * 2008-02-14 2009-10-08 Oy Granula Ab Ltd Procédé pour réduire la cytotoxicité de l'agent actif inhibant la croissance de micro-organismes et pour augmenter son effet
WO2009101261A3 (fr) * 2008-02-14 2009-10-08 Oy Granula Ab Ltd Procédé pour réduire la cytotoxicité de l'agent actif dans une composition administrée à un mammifère ou venant en contact avec un mammifère
US8431170B2 (en) 2008-11-25 2013-04-30 Oy Granula Ab Ltd. Antimicrobial composition with low cytotoxicity
US8496974B2 (en) 2008-11-25 2013-07-30 Oy Granula Ab Ltd Method for preparing a composition comprising a compound mixture and a carrier agent

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700002306A1 (it) * 2017-01-11 2018-07-11 Sinerga Group S R L 7-idrossimatairesinolo per uso nel trattamento e nella prevenzione delle patologie tricologiche e cutanee di origine infiammatoria e/o ormonale

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100514A1 (en) * 2001-11-26 2003-05-29 Markku Ahotupa Method of inhibiting overactivity of phagocytes or lymphocytes in an individual
WO2003099244A1 (fr) * 2002-05-27 2003-12-04 Beiersdorf Ag Preparation cosmetique et/ou dermatologique contenant des 2,3-dibenzyle-butyrolactones
WO2004000304A1 (fr) * 2002-06-19 2003-12-31 Hormos Medical Corporation Formulation de lignane
WO2005048970A1 (fr) * 2003-11-20 2005-06-02 Basf Aktiengesellschaft Utilisation de lignanes dans des preparations cosmetiques ou dermatologiques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7159069B2 (en) * 2004-06-23 2007-01-02 Atmel Corporation Simultaneous external read operation during internal programming in a flash memory device
FR2875701B1 (fr) * 2004-09-30 2008-08-08 Lm Cosmetics Sarl Nouvelle utilisation cosmetique ou dermatologique de lignanes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100514A1 (en) * 2001-11-26 2003-05-29 Markku Ahotupa Method of inhibiting overactivity of phagocytes or lymphocytes in an individual
WO2003099244A1 (fr) * 2002-05-27 2003-12-04 Beiersdorf Ag Preparation cosmetique et/ou dermatologique contenant des 2,3-dibenzyle-butyrolactones
WO2004000304A1 (fr) * 2002-06-19 2003-12-31 Hormos Medical Corporation Formulation de lignane
WO2005048970A1 (fr) * 2003-11-20 2005-06-02 Basf Aktiengesellschaft Utilisation de lignanes dans des preparations cosmetiques ou dermatologiques

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009101262A3 (fr) * 2008-02-14 2009-10-08 Oy Granula Ab Ltd Procédé pour réduire la cytotoxicité de l'agent actif inhibant la croissance de micro-organismes et pour augmenter son effet
WO2009101261A3 (fr) * 2008-02-14 2009-10-08 Oy Granula Ab Ltd Procédé pour réduire la cytotoxicité de l'agent actif dans une composition administrée à un mammifère ou venant en contact avec un mammifère
US8431170B2 (en) 2008-11-25 2013-04-30 Oy Granula Ab Ltd. Antimicrobial composition with low cytotoxicity
US8496974B2 (en) 2008-11-25 2013-07-30 Oy Granula Ab Ltd Method for preparing a composition comprising a compound mixture and a carrier agent

Also Published As

Publication number Publication date
DE102006008771A1 (de) 2007-08-23

Similar Documents

Publication Publication Date Title
EP0636359B1 (fr) Combination d'agents déodorants à base d'acides alcaniques alpha-omega dicarboxyliques et des acides de laine
KR102657579B1 (ko) 생원천의 연화제 조성물
DE4423410C2 (de) Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Monocarbonsäureestern von Oligoglyceriden
DE102005017032B4 (de) Kosmetische Formulierung enthaltend Mandelsäure
DE4309372A1 (de) Desodorierende Wirkstoffkombinationen auf der Basis von Wollwachssäuren und Partialglyceriden
DE19643238A1 (de) Antitranspirant- und Deodorantstifte mit hohem Wassergehalt
DE10141258B4 (de) Kosmetische und dermatologische Zubereitung und ihre Verwendung
DE102006053360A1 (de) Hautreinigungsmittel, insbesondere Kälteschutzcreme
WO2007096088A1 (fr) Préparations efficaces contre les impuretés cutanées et les formes bénignes de l'acné, contenant de l'hydroxymatairésinol comme principe actif
DE19631004A1 (de) Desodorierende Wirkstoffkombinationen auf der Basis von Wollwsaschsäuren, Partialglyceriden und Arylverbindungen
WO1994018943A1 (fr) Preparations efficaces contre les impuretes de la peau contenant des esters de di- ou de triglycerine comme principe actif
EP1361856A1 (fr) Emulsions en gel se presentant sous la forme d'emulsions huile dans l'eau contenant des hydrocolloides
DE19844261A1 (de) Kosmetische und dermatologische Zubereitungen in Form von W/O-Emulsionen mit einem Gehalt an niedermolekularen Siliconen
CN108463210B (zh) 油包水型乳化化妆品
DE102006008769A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Hydroxymatairesinol zur Hautaufhellung von Altersflecken bzw. zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
DE3886247T2 (de) Verwendung eines Haarkosmetischen Mittels zur vorbeugung von gesplissenem Haar oder gebrochenem Haar und zur Behandlung von beschädigtem Haar.
DE4215501C2 (de) Haut- und Haarpflegemittel
DE4329379C1 (de) Gegen unreine Haut und milde Formen der Akne wirksame Zubereitungen mit einem Gehalt an Wollwachssäuren
EP2100584A1 (fr) Fondation dotée d'une combinaison de filtre UV
DE4337711A1 (de) Gegen unreine Haut und milde Formen der Akne wirksame Zubereitungen mit einem Gehalt an Monocarbonsäuremonoglyceriden kurzer und mittellanger Fettsäuren
DE10326899A1 (de) Kosmetische Zubereitungen mit stabilisierten Konservierungsmitteln
WO2007096090A1 (fr) Association de substances actives comprenant les composants hydroxymatairésinol, phénoxyéthanol, et éventuellement glycérine
DE10025123B4 (de) Desodorierende Zubereitungen mit Oligoglycerinmonocarbonsäuremonoestern, Arylverbindungen und Glycerylethern
WO2002064103A2 (fr) Preparations cosmetiques et dermatologiques se presentant sous forme d'emulsions eau-huile ayant une certaine teneur en huiles de silicones et en poudre de talc
EP1908451B1 (fr) Préparations cosmétiques à l'aide d'huiles minérales pauvres en naphte

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07711557

Country of ref document: EP

Kind code of ref document: A1